Get the Stockscreener App
63.54
2.38%
-1.55
After Hours:
63.54
Corcept Therapeutics Inc stock is traded at $63.54, with a volume of 1.21M.
It is down -2.38% in the last 24 hours and up +3.98% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
See More
Previous Close:
$65.09
Open:
$65.9
24h Volume:
1.21M
Relative Volume:
1.46
Market Cap:
$6.66B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
50.43
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-12.62%
1M Performance:
+3.98%
6M Performance:
+84.55%
1Y Performance:
+193.35%
1-Day Range:
$63.19
$66.48
1-Week Range:
$63.19
$75.00
52-Week Range:
$20.84
$75.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
63.54 | 6.66B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Blue Trust Inc. Sells 8,728 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Van ECK Associates Corp Purchases New Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Reaches New 12-Month HighWhat's Next? - MarketBeat
Corcept stock down on California lawsuit (CORT:NASDAQ) - Seeking Alpha
Corcept Therapeutics stock soars to all-time high of $71.3 - MSN
New York State Teachers Retirement System Acquires 3,789 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
New York State Teachers Retirement System Purchases 3,789 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Roman Butler Fullerton & Co. Grows Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Big health insurers sue Peninsula company over its lone drug - The Business Journals
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Van ECK Associates Corp Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Allspring Global Investments Holdings LLC Has $10.60 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Abortion Drugs Market Generated Opportunities, Future Scope - openPR
Braun Stacey Associates Inc. Invests $14.94 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Certuity LLC Takes $204,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
HC Wainwright Has Optimistic Outlook of CORT Q1 Earnings - MarketBeat
Corcept Submits Application for Another Cushing's Syndrome Drug - MSN
Corcept Therapeutics (NASDAQ:CORT) Hits New 1-Year HighHere's Why - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares - MarketBeat
At Corcept Therapeutics, Hazel Hunt Chooses To Exercise Options, Resulting In $10.61M - Benzinga
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook - MSN
Corcept therapeutics director sells shares worth $149,776 - MSN
Corcept therapeutics director Daniel Swisher sells shares worth $149,776 By Investing.com - Investing.com South Africa
Yousif Capital Management LLC Sells 516 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept therapeutics director sells shares worth $149,776 By Investing.com - Investing.com Canada
Corcept therapeutics director Daniel Swisher sells shares worth $149,776 - MSN
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Research Analysts Issue Forecasts for CORT FY2029 Earnings - MarketBeat
abrdn plc Has $21.97 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics’ (CORT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Calamos Advisors LLC Sells 4,908 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Boston Trust Walden Corp Lowers Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
H.C. Wainwright maintains $80 target on Corcept Therapeutics stock - MSN
Corcept Therapeutics Inc (CORT) Stock Sees a-0.60 Decrease - The News Heater
H.C. Wainwright maintains $80 target on Corcept Therapeutics stock By Investing.com - Investing.com UK
Q3 EPS Forecast for Corcept Therapeutics Raised by Analyst - MarketBeat
Endogenous Cushing's Syndrome Market Statistics Expected - openPR
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):